Genmab — Juni 2019
-
Mon ikke godkendelsen kommer i H1. Der er jo stadig 20 dage
så hvorfor forsøge JB mon at piske en halv negativ meddelelse. De 2.5 mia er jo hjemme selv uden nogen salgsstigning med udgangspunkt i Q1 som var 630 mil x 4 = 2.516. Så jeg vil sige selv med kun 4 mdr 1 line salg er 3 bn sandlynligvis mulig -
Du kan have ret..Jyske kan have ret..jeg kan have ret...alle kan have ret.
-
Nogle håber..andre tror...men ingen ved!
-
Måske er FDA i gang med en større cost/benefit analyse.
-
altså vi når i mål med 15% stigning per kvartal
-
- maj udtaler FDA: The Real-Time Oncology Review Program is a pilot program and we are continuing to evaluate drug applications on a case by case basis" https://www.raps.org/news-and-articles/news-articles/2019/5/fda-approves-first-nda-under-real-time-oncology-re
-
Lidt ADC stuff - interessant for Zymeworks folk: Analysts say DS-8201 could triple the number of patients who get powerful targeted treatment for breast cancer, the most common tumor in women that kills more than half a million annually. As importantly, its ability to target cancer cells without affecting normal cells is a key advantage over the take-no-prisoners approach of chemotherapy.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind